NANOPARTICLES FOR USE IN THE REDIRECTION AGAINST THE TUMOUR OF A NON-TUMOUR-SPECIFIC IMMUNE RESPONSE, BASED ON A PRE-EXISTING IMMUNITY

The present patent application relates to nanoparticles for the delivery and targeting of a non-tumour-specific antigen in cancer cells, comprising a matrix support based on a biocompatible material, the non-tumour-specific antigen, and an adjuvant, for use in recalling, in cancer patients who have a specific immunity for the non-tumour-specific antigen pre-existing to the tumour pathology, the immune response specific to the non-tumour-specific antigen against the cancer cells. A further object of the application is anti-tumour pharmaceutical formulations comprising nanoparticles and kits comprising the aforementioned anti-tumour pharmaceutical formulations in combination with traditional anti-tumour vaccines..

Medienart:

Patent

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Europäisches Patentamt - (2022) vom: 20. Apr. Zur Gesamtaufnahme - year:2022

Sprache:

Englisch

Beteiligte Personen:

TORRE MARIA LUISA [VerfasserIn]
BARI ELIA [VerfasserIn]
PERTEGHELLA SARA [VerfasserIn]
FILACI GILBERTO [VerfasserIn]
FENOGLIO DANIELA [VerfasserIn]
FERRERA FRANCESCA [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

615
A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d)
A61P: Specific therapeutic activity of chemical compounds or medicinal preparations
Che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2022-04-20, Last update posted on www.tib.eu: 2022-10-16, Last updated: 2023-02-09

Patentnummer:

EP3983003

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA014451425